The survey, conducted by the International Federation of Clinical Chemistry and Laboratory Medicine’s Committee on Emerging Technologies in Pediatric Laboratory Medicine, set out to map how pediatric cardiac troponin testing is actually practiced around the world. The results, published in the journal Clinical Chemistry and Laboratory Medicine under the title Mapping pediatric cardiac troponin testing worldwide: results from the IFCC survey on emerging applications, standardization needs and access, reveal a field running on borrowed data. Among eligible respondents, 58.5 percent reported offering cardiac troponin testing in-house, yet 65.5 percent of those laboratories lacked child-specific reference intervals. In practice, most laboratories testing children rely on reference intervals designed for adults, often those supplied by assay manufacturers, even though the biology of a child’s heart and the conditions that damage it differ profoundly from those of an adult.

Reference intervals are the quiet workhorses of laboratory medicine. When a troponin result comes back, the number on the report means little on its own; it is the comparison against a validated normal range that tells the clinician whether heart muscle injury has occurred. If that range is wrong, two kinds of error follow. A threshold set too high, calibrated to adult populations with different baseline physiology, may miss genuine cardiac injury in a child, delaying diagnosis of myocarditis or another serious condition. A threshold set too low may flag healthy children as abnormal, triggering unnecessary echocardiograms, hospital admissions, and parental anxiety. Without pediatric-specific data, laboratories cannot know which kind of error they are making, or how often.

The survey found that a handful of clinics have attempted to establish child-specific troponin benchmarks, but the picture they paint is one of fragmentation rather than progress. Different clinics use different cutoffs, and there is no agreement on how the correct reference interval should be derived in the first place. Some may have used small local cohorts of healthy children, others may have adapted manufacturer data or published studies conducted on different analytical platforms. Because troponin assays themselves vary between manufacturers, with different antibodies and different detection limits, a cutoff validated on one platform cannot simply be transferred to another. The result is a patchwork in which the same child, with the same underlying condition, might receive a different interpretation depending on which hospital’s laboratory processed the sample.

Most clinicians and laboratory specialists who responded to the survey identified this absence of consistent, validated child-specific guidelines as a major obstacle to providing children with reliable heart care. The problem is not simply that the data are missing; it is that the clinical questions asked of troponin testing in children are fundamentally different from those asked in adults. Heart attacks are rare in childhood, so the adult paradigm of using troponin to confirm or exclude myocardial infarction rarely applies. Instead, pediatricians deploy troponin testing across a remarkably wide range of conditions that have little in common with adult coronary disease, including heart infections such as myocarditis, Kawasaki disease with its inflammatory damage to coronary arteries, and cardiac injury caused by cancer treatment, a growing concern as survival rates for childhood cancer continue to climb.

This diversity of clinical contexts changes what a reference interval would even mean. A single normal range borrowed from a population of healthy children assumes that one threshold can serve every purpose, but the survey’s authors argue that this assumption fails. A child undergoing chemotherapy may sustain low-level cardiac injury that matters enormously for long-term outcomes but produces troponin values far below the threshold relevant to acute myocarditis. Conversely, the inflammatory storm of Kawasaki disease may drive troponin concentrations to levels that would be catastrophic in an adult yet be expected in that pediatric context. The researchers contend that troponin testing in children needs different benchmarks tailored to each specific condition, rather than one generic reference range applied broadly across all clinical scenarios.

The technical challenges behind building those benchmarks are considerable. Establishing a pediatric reference interval requires recruiting sufficient numbers of healthy children across multiple age bands, from neonates through adolescents, because troponin physiology changes with development. Samples must be analyzed on defined platforms with characterized analytical performance, and statistical methods for partitioning the data by age and sex must be agreed upon in advance. For condition-specific thresholds, the task is harder still: researchers need cohorts of children with each disease, followed long enough to know which troponin values actually predict outcomes that matter, such as reduced heart function, need for intensive care, or late cardiovascular complications. No single laboratory can generate that evidence alone, which is why the survey’s authors frame the problem as one requiring coordinated global action rather than isolated local fixes.

That call for coordination is echoed in the study’s leadership. Dr. Lianna G. Kyriakopoulou, Director of Genome Diagnostics at The Hospital for Sick Children and the University of Toronto in Canada, said the committee was driven by the belief that children deserve diagnostic care built around their biology, not borrowed from adult medicine. To advance precision child health, she said, the field now needs coordinated global action to develop pediatric reference intervals, strengthen clinical guidance, and ensure every child receives results that are accurate, meaningful, and equitable. The framing of equity is significant: laboratories in well-resourced centers may at least be aware of the limitations of adult-derived cutoffs, while facilities with fewer resources may have no way to know their pediatric results rest on uncertain ground.

The survey also highlights a structural gap between the pace of assay development and the pace of pediatric validation. Cardiac troponin assays have become extraordinarily sensitive over the past two decades, capable of detecting injury at concentrations once invisible, and manufacturers have raced to bring high-sensitivity platforms to market. Adult populations, with their large volumes of chest-pain presentations, provide the datasets needed to validate those assays quickly. Children, whose testing volumes are smaller and whose indications are scattered across many rare conditions, do not generate comparable data through routine care. Unless pediatric-specific studies are deliberately funded and designed, the market alone will not close the gap, and laboratories will continue to default to manufacturer-provided adult intervals because those are the only numbers available on the package insert.

For practicing clinicians, the survey’s message is a call for caution and for advocacy. A troponin result in a child should be interpreted with an explicit understanding of what reference interval was applied and how it was derived, and where child-specific data are absent, results should be correlated with imaging, clinical course, and other biomarkers rather than acted upon in isolation. For laboratory directors, the findings argue for transparency about the limitations of current intervals and for participation in the multi-center collaborations that the IFCC committee is promoting. And for funders and professional societies, the study is evidence that pediatric laboratory medicine remains an underbuilt discipline in which even a test as routine as troponin rests, for most of the world’s children, on data borrowed from their parents’ medicine. Closing that gap, the authors suggest, is not a technical luxury but a prerequisite for giving children the same standard of diagnostic certainty that adults have long enjoyed.

Subject of Research: Pediatric cardiac troponin testing and the lack of child-specific reference intervals

Article Title: Mind the child heart gap

Article References: Mind the child heart gap. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cardiac troponin, pediatrics, reference intervals, laboratory medicine, IFCC, myocarditis, Kawasaki disease, cancer treatment, clinical chemistry, heart injury, diagnostic testing, global survey

The technical problem at the heart of the debate concerns the hypopnea, defined as a partial reduction in airflow during sleep, in contrast to a complete apnea. Standard polysomnography records airflow through nasal pressure cannulas and thermal sensors, alongside respiratory effort belts and oximetry that tracks blood oxygen. Obstructive events are those in which effort continues while the airway collapses; central events are those in which the brain simply stops issuing the neural commands to breathe. Hypopneas, because they are partial, sit awkwardly in this binary scheme. A shallow breath can arise from a partly closed airway, from a weak central drive, or from a combination of the two, and the signal differences on a routine recording can be subtle enough that scorers disagree.

This ambiguity matters because the two categories point to different physiology and, potentially, different treatments. Obstructive events respond to continuous positive airway pressure, oral appliances, and airway-focused interventions. Central events, which reflect instability in the feedback loop that controls ventilation, may respond poorly or even paradoxically to standard pressure therapy, and are managed with different tools entirely, from adaptive servo-ventilation to medications that adjust chemosensitivity. If a hypopnea that is truly central in origin is counted as obstructive, a patient may receive a diagnosis whose treatment pathway is mismatched with the underlying mechanism.

The letter builds on a recent position paper in the same journal in which Ahn, Azarbarzin, Badr, Berry, and colleagues argued that classifying central hypopneas is important enough to warrant coordinated action by the sleep medicine community. Kumari’s contribution extends that argument by asking a more fundamental question: what is the point of identifying an event if knowing its type does not change what happens to the patient next? Drawing on a framework for evaluating diagnostic tests developed by di Ruffano, Hyde, McCaffery, Bossuyt, and Deeks in the British Medical Journal, she frames central hypopnea classification not as a scoring exercise but as a test whose value must be demonstrated in a chain that runs from detection, to differential diagnosis, to treatment selection, to measurable improvement in health.

That framework, originally developed to help researchers design trials of diagnostic technologies, imposes a discipline that sleep scoring has largely escaped. A diagnostic test earns its place in clinical practice by showing that its results lead to better decisions and better outcomes, not merely that it produces numbers. Applied to hypopnea classification, the question becomes whether knowing that a given hypopnea is central rather than obstructive actually alters management in ways that benefit the patient. The letter suggests that the field cannot answer this question with confidence, because the necessary evidence linking event phenotype to treatment response has never been systematically assembled.

The second pillar of the argument comes from a consensus statement led by Malhotra, Ayappa, Ayas, Collop, Kirsch, and McArdle, published in the journal Sleep, on metrics of sleep apnea severity beyond the apnea-hypopnea index. That statement catalogued the shortcomings of the AHI, the single number that has dominated sleep medicine since its inception. The AHI counts all apneas and hypopneas per hour of sleep regardless of type, position, or physiological consequence. Two patients with identical AHI values can carry very different burdens of disease: one may have long, severely desaturating events concentrated in REM sleep, while the other has short, benign events scattered across the night. Collapsing this heterogeneity into one figure discards exactly the information that might guide treatment.

Central hypopneas sit at the sharp edge of this metric problem. Because scoring rules allow hypopneas to be identified through airflow reduction with or without associated desaturation or arousal, depending on the rule set in use, the same recording can yield different AHI values under different guidelines. When central events are lumped together with obstructive ones, the resulting index reflects neither the mechanical burden of airway collapse nor the control-system instability of central apnea. For conditions in which central events predominate, such as heart failure-associated central sleep apnea or opioid-induced respiratory depression, an AHI that blends event types may actively mislead the clinician about both severity and prognosis.

The physiological stakes are considerable. Central respiratory events arise from instability in the loop gain of the ventilatory control system, the sensitivity with which the brain responds to fluctuations in carbon dioxide and oxygen. High loop gain produces overshoot and undershoot in ventilation, creating cyclical patterns such as Cheyne-Stokes breathing. This instability is not a mechanical problem that a splinted airway can fix; it is a control problem with its own pharmacology and its own device solutions. Identifying central hypopneas is therefore a step toward measuring loop gain and control instability in ordinary clinical recordings, which could eventually allow clinicians to select patients for servo-ventilation or other control-targeted therapies on a rational basis rather than by trial and error.

The letter also highlights the human cost of the status quo. Patients whose symptomatic breathing disturbances are scored as mild or equivocal may be denied insurance coverage for therapy, told their sleep study was normal, or left to cycle through ineffective treatments. Conversely, patients whose events are counted but whose event type is misclassified may undergo positive airway pressure trials that fail, reinforcing a cycle of non-adherence and clinical frustration. Kumari argues that rigorous, clinically validated classification of central hypopneas would sharpen the diagnostic pathway at both ends, directing the right patients to the right interventions and sparing others inappropriate treatment.

The path forward, as the letter sketches it, follows the logic of the diagnostic-test framework: define the clinical decision the classification is meant to inform, gather evidence that the distinction changes that decision, and then test whether patients whose management is guided by event type fare better than those managed on AHI alone. That program requires agreement on scoring criteria for central hypopneas, prospectively collected data linking event phenotype to treatment response, and trial designs that treat classification as an intervention in its own right. None of this is easy, and the letter does not pretend otherwise. Its central claim is simpler and harder to dismiss: a measurement that has never been shown to change a clinical decision is a measurement awaiting justification, and for central hypopneas the justification has not yet been built. As sleep medicine moves toward richer phenotyping of sleep-disordered breathing, closing the gap between event identification and clinical utility has become the test that the field’s most familiar number must finally pass.

Subject of Research: Clinical classification of central hypopneas in sleep-disordered breathing diagnosis and the validation of diagnostic utility

Article Title: Central hypopnea classification: bridging the gap between event identification and clinical utility

Article References: Kumari, N. (2026). Central hypopnea classification: bridging the gap between event identification and clinical utility. Journal of Clinical Sleep Medicine, 22(1), Article 172. https://doi.org/10.1007/s44470-026-00202-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00202-8

Keywords: central hypopnea, sleep apnea, polysomnography, apnea-hypopnea index, sleep medicine, respiratory events, diagnostic testing, loop gain, positive airway pressure, sleep-disordered breathing, Journal of Clinical Sleep Medicine, Central